ABSTRACT: Multidrug resistance (MDR) is a major cause of chemotherapy failure in the clinic. Drugs that were once effective against naïve disease subsequently prove ineffective against recurrent disease, which often exhibits an MDR phenotype. MDR can be attributed to many factors; often dominating among these is the ability of a cell to suppress or block drug entry through upregulation of membrane-bound drug efflux pumps. Efflux pumps exhibit polyspecificity, recognizing and exporting many different types of drugs, especially those whose lipophilic nature contributes to residence in the membrane. We have developed a general strategy to overcome efflux-based resistance. This strategy involves conjugating a known drug that succumbs to efflux-mediated resistance to a cell-penetrating molecular transporter, specifically, the cell-penetrating peptide (CPP), D-octaarginine. The resultant conjugates are discrete single entities (not particle mixtures) and highly water-soluble. They rapidly enter cells, are not substrates for efflux pumps, and release the free drug only after cellular entry at a rate controlled by linker design and favored by target cell chemistry. This general strategy can be applied to many classes of drugs and allows for an exceptionally rapid advance to clinical testing, especially of drugs that succumb to resistance. The efficacy of this strategy has been successfully demonstrated with Taxol in cellular and animal models of resistant cancer and with ex vivo samples from patients with ovarian cancer. Next generation efforts in this area will involve the extension of this strategy to other chemotherapeutics and other MDR-susceptible diseases. KEYWORDS: molecular transporters, cell-penetrating peptide (CPP), guanidinium-rich molecular transporters, octaarginine, multidrug resistance, cancer, drug delivery, P-glycoprotein
■ INTRODUCTION
The development of treatments for multidrug resistant (MDR) disease is one of the greatest challenges in medicine. MDR is a ubiquitous problem, being associated with diseases such as cancer, bacterial, parasitic, and viral infections. The World Health Organization estimates, for example, that there were over 450,000 new MDR tuberculosis cases worldwide in 2012 alone. 1, 2 For cancer, chemotherapy fails in over 90% of patients with metastatic cancer, an outcome driven in large measure by MDR. 3 MDR is a multifaceted problem caused by a number of different mechanisms, including drug efflux, target mutation, 4 cell cycle effects, drug metabolism, 5 apoptosis evasion, 6 and altered membrane permeation. 5, 7 Drug efflux is often a dominating mechanism in many MDR cases across disease types, including cancer, 5 malaria, 8 and tuberculosis. 9 Drug efflux arises from an energy-dependent transport of a drug out of the cell or its membrane mediated by membrane-associated protein pumps, such as P-glycoprotein (Pgp, also known as ABCB1 or MDR1) (Figure 1) . 10 While MDR and strategies to overcome it are subjects of considerable breadth associated with many diseases, in this review, emphasis will be placed on MDR cancer, the role of Pgp efflux pumps in disrupting the effective treatment of cancer, and strategies for overcoming this effluxbased resistance.
Several efflux pumps are known to be associated with MDR, 5 the most prevalent of which is Pgp. 11 As a member of the adenosine triphosphate-binding cassette (ABC) superfamily, Pgp is a promiscuous transmembrane protein that exhibits the remarkable ability to recognize and export numerous xenobiotics and toxins from the cell. In striking contrast to the impressive structural specificity of many proteins for their substrates, Pgp exhibits polyspecificity, recognizing and exporting numerous structurally diverse molecules with molecular weights from 330 to 4000 Da. 12, 13 This uncanny ability to recognize structurally different agents is attributed to a selectivity filter based upon physical properties and a wellplaced location in the plasma membrane. Its substrate molecules, while differing in structure, are generally hydrophobic in nature and thus partition into the nonpolar membrane, where Pgp resides.
14 These hydrophobic substrates include widely used classes of chemotherapeutic agents, such as taxanes, vinca alkaloids, anthracyclins, kinase inhibitors, and camptothecins that often are rendered ineffective due to Pgp export. 5 In 2009, a ground-breaking study by Aller and colleagues reported the crystal structure of mouse Pgp, which shares 87% sequence homology with human Pgp, to a resolution of 3.8 Å. 15 This unique study revealed that Pgp has portals open to both the cytoplasm and the inner leaflet of the cell membrane, allowing for effective collection and expulsion of lipophilic substrates that are preferentially solubilized in the membrane ( Figure 1B,C ). An unfortunate outcome of drugs designed for passive diffusion across the nonpolar membrane of a cell is that they are often substrates for Pgp export due to their residence time in the membrane.
Many studies link Pgp expression to resistant and recurrent cancers. However, one of the challenges associated with quantifying the extent of this link is the difficulty of measuring Pgp expression levels. 16 Despite these challenges, taxane resistance caused by Pgp efflux has been well characterized in vitro and has been shown to play an important role in recurrent ovarian 17 and breast 18 cancers. Increased expression of Pgp has also been found to track with a poor response to taxane-based therapy in nonsmall-cell lung cancer. 19, 20 It has additionally been shown that recurrent ovarian cancers have higher levels of Pgp expression on a population basis. 17 Of great significance in efforts to understand how some cells evade chemotherapy, efflux pumps have been more broadly implicated in the proposed stem cell-like behavior of certain cancer cell populations, 21 which is of importance in emerging theories on cancer resistance. While the cancer stem cell hypothesis is for some still a subject of debate, there have been many recent, high-profile studies in several different cancer types that further support its role in cancer. 22−24 The not uncommon view that cancer cells are largely homogeneous and that recurrence occurs when debulking chemotherapy causes or selects upregulation of resistance factors (Figure 2A ) is giving way to emerging evidence for stem cell-like behavior of many cancer cells. The cancer stem cell hypothesis proposes that there is a heterogeneous mix of cancer cells in a tumor, and some cells can regenerate the entire tumor, like embryonic stem cells can generate an entire organism. 21 The stem-like cancer cells already have high expression levels of efflux-pumps and other resistance factors and are thus not cleared by initial rounds of chemotherapy. As a result, the cancer stem-like cells seed disease recurrence, and the recurrent disease is thus chemoresistant ( Figure 2B ). Efflux pump expression, including Pgp, has long been considered a hallmark of stem cells. 25−27 Moreover, high levels of pump expression have also recently been found for a variety of stem cell-like tumor cells, such as leukemia 28 and osteosarcomas. 29 The cancer stem cell hypothesis implies that without utilizing or developing therapies that can avoid or overcome efflux-mediated resistance, including Pgp, chemotherapy would only reduce tumor burden and slow disease progression but not eradicate the pool of progenitor cancer cells.
Several distinct strategies have been pursued to abrogate Pgp-mediated resistance in multidrug resistant cancer. These strategies include:
1. Development of new agents or modification of existing therapeutic agents such that they are no longer Pgp substrates; 2. Pgp pump inhibition with coadministration of existing chemotherapeutics; 3. Inhibition of Pgp expression through the use of RNA interference; 4. Attachment or complexation of an existing chemotherapeutic to a drug delivery agent, including molecular transporters such as the cell-penetrating peptide, Doctaarginine, to overcome Pgp-mediated efflux. Each strategy is described in more detail below, with a focus on the significant and broad-spectrum opportunity that cellpenetrating agents such as peptides and other molecular transporters provide as a means to overcome pump-mediated efflux in MDR disease with a potentially rapid path to the clinic.
1. Development of New Agents to Avoid EffluxMediated MDR. Of the strategies for overcoming MDR noted above, the search for new agents that are not Pgp substrates has justifiably attracted attention. This search has taken two forms: the identification of new leads or the modification of existing drugs. The former, based largely on screening natural product or synthetic libraries, is attractive but has a long path to the clinic. Paclitaxel, for example, took approximately 30 years to advance from first "hit" to clinical use. 30 An example of a new drug derived by modification of an existing drug is the newly approved taxane, cabazitaxel (trade name Jevtana), a SanofiAventis therapy that was approved for hormone-refractory prostate cancer in 2010 ( Figure 3) . 31 This new semisynthetic taxane was found to have similar potency and side effect profiles to other taxanes, but it displays a decreased susceptibility to efflux by Pgp. 32 Because of this decreased susceptibility to Pgp export, it showed clinical activity in women with taxaneresistant metastatic breast cancer. 33 However, it is not yet approved for this indication.
In addition to the development of small molecule candidates that avoid Pgp efflux, considerable effort has gone into the development of nanomaterials that do not serve as Pgp substrates, such as Tat-functionalized nanocrystalline silver agents. 34 2. Pgp Pump Inhibition to Overcome Drug Efflux. In addition to tuning existing drugs or finding new ones, another strategy to overcome efflux-mediated resistance, under investigation for over 30 years, is based on inhibiting Pgp with small molecules. 35 Toward this end, many modulators/ inhibitors of ABC transporters have been developed, but cytotoxicity and the complex pharmacokinetics of interdependent drugs (codosed inhibitor and anticancer drugs) have slowed the clinical implementation of this approach. An important and challenging aspect of inhibiting Pgp export is that export pumps are required for normal cell function. 5 Several generations of pump inhibitors have been developed and tested, and they are extensively covered in recommended reviews. 5,6,35−38 As brief context for this review, the first compound identified as a Pgp inhibitor was verapamil, a calcium channel blocker, whose advancement was hampered by cardiovascular side effects. 39, 40 Other first-generation inhibitors included the immunosuppressant, cyclosporine A, 41 and the antimalarial, quinine. 42 These Pgp inhibitors generally displayed low affinity and low specificity for Pgp, thus requiring high doses that often elicited undesired side effects. Second generation Pgp inhibitors were developed through structural modifications of the first generation agents. While they displayed improved Pgp modulation, they also showed adverse pharmacokinetic interactions with cytochrome P450 (CYP450), leading to both decreased efficacy and increased toxicity. 6, 43 On the basis of extensive structure−activity relationships (SAR) studies on previous inhibitors, the third generation Pgp inhibitors were designed to optimize the pharmacophoric elements necessary for Pgp specificity and to avoid pharmacokinetic interactions with known chemotherapeutics. 36 Additionally, CPP−chlorambucil conjugates have also been reported to function as Pgp inhibitors. 44 Although there have been several Pgp inhibitors tested in clinical trials, significant clinical benefit has yet to be achieved. 45 Pgp pump inhibition remains, however, an actively pursued strategy for overcoming MDR.
3. Inhibition of Pgp Expression Through the Use of RNA Interference. There are other experimental strategies under investigation for the inhibition of Pgp. One recent strategy is to achieve formal Pgp inhibition by blocking Pgp synthesis through the use of RNA interference (RNAi). 46, 47 RNAi is an endogenous mechanism by which post-transcriptional gene silencing is achieved in a sequence-specific manner using double-stranded RNA molecules, including short interfering RNA (siRNA). 48 Relative to small molecule Pgp inhibitors, RNAi technology circumvents many adverse pharmacokinetic effects that could result from drug interactions. The specificity of RNAi could also reduce off-target effects observed with small molecule inhibitors. Although there are several potential advantages to RNAi-mediated inhibition of Pgp expression, there are numerous complex barriers to achieving successful clinical use of siRNA, the first and foremost being delivery of siRNA into cells. Most reported studies on silencing export pumps with siRNA employ commercially available transfection reagents, largely limiting their findings to in vitro studies. 49−51 The first reported animal model for Pgp downregulation utilized chemically-modified Stealth RNAi against Pgp in nude mice bearing lung carcinoma tumors. 52 Transfection was achieved using electroporation, resulting in ∼60% reduction in tumor size after 2 weeks of cotreatment with vinorelbine. A 2010 study by Patil and coworkers reported a dual agent poly(D,L-lactide-co-glycolide) nanoparticle, encapsulating both Taxol and a Pgp-targeted siRNA. 53 A 50% reduction in tumor size was observed after 16 days of treatment, demonstrating the feasibility of systemic administration. It is important to note, however, that Pgp is critical for normal physiological function, 5 and thus nonselective inhibition can cause an on-target toxicity common to all Pgp inhibitors.
4. Molecular Transporters for Overcoming EffluxMediated MDR. A distinct strategy for overcoming Pgpmediated efflux and associated MDR is based on the use of drug delivery agents that modify the mechanism of cellular entry of a drug and thus avoid Pgp export. This strategy avoids the need for Pgp inhibition and the attendant challenges with the "double drugging" of interdependent drugs as described previously. Not long after the discovery of the importance of Pgp in MDR, researchers hypothesized that changing the mechanism of uptake of a drug might overcome Pgp-mediated resistance. 54 Sť'astnýand co-workers conjugated the targeting moieties anti-CD71, antithymocyte globulin, anti-CD4, and transferrin to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers containing doxorubicin. 55 The results of this study indicated that by changing the mechanism of cellular uptake of the drug, conjugation to targeting agents could partially overcome Pgp-mediated MDR. Doxorubicin has also been conjugated directly to the targeting agent, transferrin, and subsequently shown to have activity in multidrug-resistant KB cell lines. 56 However, this cytotoxicity appears to be via a different mechanism than the parent doxorubicin. 57 Transferrin has also been used in conjunction with doxorubicinencapsulated liposomes to overcome a Pgp-based MDR phenotype. 54, 58 Though these studies support the potential of using targeting moieties to alter the uptake mechanisms of a chemotherapeutic, thereby avoiding MDR, there has been limited work to investigate these agents in vivo.
Conjugation of a chemotherapeutic to a molecular transporter changes both its physical properties and its mechanism of cellular uptake, 59 ,60 thus serving as a general strategy to evade Pgp efflux. Currently, there are only a few examples of this strategy: the use of Taxol−oligoarginine conjugates to overcome resistance in vitro, in vivo, and ex vivo in malignant human ascites; 61,62 the use of conjugates of doxorubicin with several different cell-penetrating peptides such to overcome MDR, 63, 64 and phage-discovered CPP conjugates of methotrexate. 65 These studies on this approach will be expanded upon and discussed in more detail in the following sections. In brief, drug−transporter conjugation represents a powerful and general strategy to not only improve drug formulation and control drug release but also target drug delivery and most importantly to overcome resistant disease. By fixing the shortcomings of a known drug, this drug-rescue strategy could have a fast track to clinical trials. It can also be used to overcome formulation, distribution, and targeting problems associated with drug leads and screening strategies.
Molecular transporters are a class of agents that enable or enhance the passage of drugs or probes across biological barriers. 59,66−68 While often referred to, using a structurally limiting terminology, as cell-penetrating peptides, the term "molecular transporters", introduced by us in 2000, serve to more generally cover the many structural classes of molecules that exhibit cell-penetrating behavior. This terminology framed the more general expectation and now widely demonstrated finding that many nonpeptidic systems could function in a fashion similar or superior to cell-penetrating peptides. Indeed, Wender, Rothbard, and co-workers first reported that the uptake of the CPP, Tat 49−57 (RKKRRQRRR), is a function of its arginine content and not its peptide backbone and more generally proposed that transport into the cell is due to the number and spatial array of its guanidinium groups. 69 Multiple mechanisms have been advanced to explain the paradoxical behavior of an oligocation and thus highly water-soluble and polar agent crossing the nonpolar cell membrane to enter cells. 59 Both adaptive translocation and endocytotic mechanisms have been proposed and evidence indicates that some proposed mechanisms work simultaneously. 70 Robust uptake is generally observed for a variety of cell types, although there are differences in rates and mechanisms of uptake depending on cell line, cargo, and transporter variations. 59 Mechanistically, the guanidinium groups are proposed to form bifurcated hydrogen bonds with cell surface anions (e.g., carboxylates, sulfates, and phosphates), and the resultant, charge-neutralized complexes are driven inward by the polarization of the membrane or by encapsulation in an endosome. 60 Guanidinium-rich molecular transporters thus function as "polarity chameleons", being highly water-soluble in the extracellular milieu but becoming nonpolar upon complexation with membrane components, allowing for rapid cellular uptake.
The finding by Wender, Rothbard, and co-workers that the number and spatial array of guanidinium group controls cellular uptake provided a blueprint for the design of the first cellpenetrating guanidinium-rich peptoid transporters, 69 followed by oligocarbamates, 71 dendrimers, 72, 73 oligocarbonates, 74 carbohydrates, 75 and other transporters. 66 Cell-penetrating guanidinium-rich molecular transporters have been shown to enable or enhance cellular uptake of small molecules, probes, imaging agents, metals, peptides, proteins, siRNA, DNA plasmids, quantum dots, and vesicles. 59, 66, 67 In addition to passage across cell membranes, guanidinium-rich molecular transporters have also been shown to cross skin, ocular, buccal, and blood−brain barriers, and have been advanced into clinical trials. 66 The use of molecular transporters to improve or change the cellular uptake profile of drugs and probes has been exploited for many different applications from basic research to clinical evaluation. 66 It is noteworthy that guanidinium-rich conjugates are both highly water-soluble and rapidly enter cells, characteristics of great importance in avoiding Pgp export associated with MDR (Table 1) . Their properties and performance thus provide a powerful and general strategy for avoiding Pgp-based efflux. Our working hypothesis was that the properties and thus cellular uptake of a drug, which, because of its lipophilicity, would spend time in a membrane and thus be a substrate for Pgp export, could be altered by conjugation to a transporter to avoid Pgp export and promote cellular entry. Because of conjugation to the oligo-cationic transporter, the drug conjugate would be rendered highly water-soluble, spend little time in the nonpolar membrane, and rapidly enter cells, thus evading Pgp export (Figure 4) .
Early work in this area was largely limited to nonreleasable conjugates of doxorubicin and its derivatives. Temsamani and co-workers tested doxorubicin coupled to two different cellpenetrating peptidic transporters, D-penetratin and pegelin, 16 and 18 amino acids in length, respectively, to form nonreleasable conjugates that displayed improved accumulation in resistant K562/ADR cells. 76 Liang and Yang also synthesized a nonreleasable doxorubicin conjugate, 77 utilizing the cellpenetrating Tat peptide. 78−80 They found improved cell kill of the Tat conjugate relative to free doxorubicin in drugresistant MCF-7 cells and suggested that this improvement was likely due to a change in the mechanism of uptake relative to the free drug alone. 77 Aroui and co-workers also reported a comparative study on doxorubicin conjugated to either Tat or penetratin, which showed different cell kill profiles depending upon both CPP identity and cell line. 64 Additionally, doxorubicin was conjugated to a small series of proprietary peptides, named Vectocell peptides, that were developed to transport molecules across cell membranes via endocytosis. 81 The authors found that a peptide−doxorubicin conjugate coupled through an ester linkage showed increased antitumoral activity against both doxorubicin-sensitive and -resistant cancer models. 63 This Vectocell conjugate also displayed better efficacy than doxorubicin alone in a partially drug-resistant in vivo tumor model. Lindgren and colleagues also reported the nonreleasable conjugation of methotrexate to a CPP identified by phage display, which killed resistant breast cancer cells more efficiently than unconjugated drug. 65 Though this early work had focused largely on nonreleasable transporter conjugates, we sought to design and test a system that would allow release of a cargo, preferably only inside of the cell. Such a strategy would allow an inactive drug conjugate to be loaded into a cell, after which the free, active drug would be released at a rate controlled by linker design. To explore this idea, in 2006, we introduced an analytical method that allows one to measure in real time, in vitro and in vivo, cellular uptake, cargo release, and cargo turnover using an optical probe (luciferin) as the cargo and luciferase as its intracellular target ( Figure 5A ). 82 The first generation strategy was based on a disulfide-containing linker that would allow for controllable release of cargo only inside the cell, mediated by the higher intracellular concentrations of glutathione (GSH). 82−84 In this approach, a disulfide bond between the transporter and cargo (luciferin) is cleaved by GSH, producing a free thiol that cyclizes into a pendant ester or carbonate, releasing free cargo (luciferin), which is then turned over by firefly luciferase with emission of one photon/turnover event. Only free luciferin is a substrate for luciferase, and every turnover event is marked by release of a photon that is counted by an extracellular chargecoupled device (CCD) camera. Thus, the process emulates and measures the equivalent of drug delivery, release, and turnover with a surrogate drug probe (luciferin). This real time quantification method was shown to be effective in both cells 82 and animals. 85 In 2008, we sought to explore the generality and effectiveness of this transporter conjugation strategy in overcoming Pgpmediated efflux with an octaarginine conjugate of coelenterazine H ( Figure 5B) . 61 Coelenterazine H is a bioluminescent substrate for intracellular Renilla luciferase and emits a photon with each turnover event. As a lipophilic heterocycle, it is also a substrate for Pgp-mediated efflux. 86 Ovarian cancer cells (OVCA-429) with a low expression level of Pgp exports pumps, when treated with either coelenterazine H or a releasable coelenterazine−transporter conjugate, exhibit a bioluminescent signal indicating that both the free probe and probe conjugate enter cells. 61 However, when the same experiment was repeated with an MDR ovarian cancer cell line, OVCA-429T, bioluminescence was observed for the coelenterazine conjugate but not for coelenterazine H alone. Significantly, the octaarginine−coelenterazine H conjugate produced similar bioluminescent signals in both resistant and nonresistant cell lines, indicating that it is not affected by Pgp export. As further evidence that a Pgp-evading mechanism was operative in overcoming the resistant phenotype, cotreatment with a known Pgp inhibitor, cyclosporine A, restored the bioluminescent signal for coelenterazine H but did not significantly affect the signal output from the octaarginine− coelenterazine conjugate. In addition to providing evidence of the ability of transporters to avoid Pgp-mediated efflux, these studies suggest that this approach might have generality for many probes and drugs that are Pgp substrates.
On the basis of these results, we set out to examine whether the efficacy of a known drug that succumbs to Pgp-based resistance could be restored simply through releasable conjugation to a molecular transporter. Taxol was selected because of its widespread use against many different types of cancers and its known tendency to develop tumor resistance. Taxol is widely used for the treatment of lung, breast, and ovarian carcinomas, 30 as well as for Kaposi's sarcoma and others. 87 While collected patient data is difficult to assess, the market size for taxanes, a measure of its clinical utility, is estimated to be $3 billion annually. 88 However, despite this clinical and commercial success, Taxol is ineffective against various types of resistant cancer. As a nonpolar drug, Taxol is soluble in nonpolar membranes, thus having a higher residency time there and a higher probability of Pgp-mediated efflux from the cell. 89 Because less drug gets into the cell and thus to its target, Taxol shows reduced activity against MDR tumors. 17, 18, 20 Increasing the dose of Taxol to offset efflux loss and force more intracellular accumulation is not an option, as that would cause greater off-target toxicities. However, a releasable Taxol−transporter conjugate that is not a substrate for Pgp export would evade export and release free Taxol in a cell at a concentration and rate determined by linker design (Figure 4) . 61, 82 Of additional significance, octaarginine conjugates of Taxol, in contrast to the free drug, are highly water-soluble, 90 allowing for dramatically reduced formulation volume, and thus administration times, and eliminating the need for toxic excipients, such as Cremophor EL. 91 The release of free Taxol from these conjugates is induced by the cleavage of a disulfide bond by intracellular glutathione, which has a higher concentration in ovarian tumor-derived ascites than in the surrounding lymphocytes, macrophages, and mesothelial cells. 92 Further, by releasing Taxol only inside a cell at a rate controlled by linker design, these conjugates allow for sustained release, thereby avoiding bolus effects and minimizing repeated or prolonged administration procedures that place burdens on both patients and clinicians.
In our efforts to examine whether the efficacy of Taxol, which succumbs to Pgp-based resistance, could be restored through conjugation to a molecular transporter, we focused our studies on models of epithelial ovarian cancer. Ovarian cancer is the leading cause of death for gynecologic malignancies, with 140,000 deaths and 220,000 new cases diagnosed each year worldwide. 93 The current standard front-line therapy for advanced ovarian cancer is surgical elimination of all visible diseases, if technically feasible, followed by a combination platinum-and taxane-based regimen. 94 While the majority of patients respond initially to this therapy, most patients subsequently develop recurrent disease. This recurrent disease is often chemotherapy resistant, with poor survival outcomes. Neither extending the time of treatment with Taxol, nor adding a third chemotherapeutic agent to the platinum/taxane frontline therapy improve overall survival. 95, 96 Recently, the National Cancer Institute recommended the administration of Taxol via intraperitoneal (IP) injection due to promising clinical results for ovarian cancer treatment. 97 IP administration has several advantages including localized delivery directly to the targeted tissue, minimizing systemic exposure, which reduces off-target effects. In addition, IP-administered Taxol has a much longer dwell time, thus providing a "depot" effect or a metronomic chemotherapy. Interestingly, Futaki and co-workers recently showed that intravenous (IV) administration of D-octaarginine to tumor-xenografted mice resulted in high accumulation of the transporter in tumor xenografts, 98 a preliminary indication that IV-injectable formulations of transporter−drug conjugates could also be used for treating certain resistant tumors.
In 2008, our lab demonstrated that these Taxol−octaarginine conjugates outperform Taxol alone in a panel of both Taxolsensitive and Taxol-resistant ovarian cancer cell lines and enhance survival in tumor-bearing animals. 61 Taxol_octaargi-nine conjugates, along with their hydrolytic stability (measured as a half-life under assay conditions) and release rates (measured as a half-life under reducing conditions) are shown in Table 2 . 61, 62 Taxol was attached to the octaarginine transporter at either the C2′ or the C7 position using a series of bioactivatable disulfide linkers ( Table 2 ). The two positions of attachment were selected due to their expected difference in activity upon modification. Modification of the free alcohol at the C2′ position of Taxol is known to significantly diminish efficacy; 99 thus, drug release would be necessary for activity. Previous studies have shown Taxol can undergo modification at C7 without a significant loss of activity; 30 thus, C7−transporter conjugates were also prepared. The linkers used in these conjugates varied in substitution at the α position of the ester linkage attached to Taxol, from unhindered to geminal dimethyl substituents. Further variations included connectivity through a carbonate linkage and varying the length of the linker. The conjugates used for these studies displayed a wide range of stabilities under physiological conditions, with halflives ranging from hours to weeks, though they all rapidly release free drug in a reducing environment (minutes to hours). In short, they can be readily tuned for shelf stability and for intracellular release.
A variety of human ovarian cancer cell lines were tested, including Taxol-sensitive UCI-101, SCOV-3, OVCA429, and OVCA433 cells, along with Taxol-resistant variants, such as OVCA429T, OVCA433T, and MCF-7-Pgp. 61 In all cell lines, b Assay conditions for prodrug stability: 10 mM dithiothreitol (DTT), HBS, pH 7.4, 37°C . the releasable Taxol−octaarginine conjugates outperformed Taxol alone, with major differences (4−100-fold) in resistant cell lines. A Tubulin polymerization assay and a cell cycle assay of the conjugates were used to determine whether Taxol and the Taxol conjugates shared a common mechanism of action ( Figure 6 ). As expected, the greatest loss in cell viability was found for cells in G 2 /M interphase for both conjugates and Taxol alone. In vivo, mice inoculated with either UCI-101 ovarian tumor cells or with Taxol-resistant OVCA429T cells showed improved survival when dosed IP with the releasable Taxol−octaarginine conjugates as compared to Taxol alone ( Figure 7) . The choice of conjugates to evaluate in each study was made to minimize the number of mice used while maximizing results obtained. Compound 3a was chosen for evaluation in the resistant OVCA429 tumor model because it produced the highest percentage of cells arrested in the G 2 /M phase in the resistant 429T line ( Figure 6B ). Because of multiple differences between 2a and 3a (e.g., location of transporter attachment, hydrolytic stability, release rate, etc.), 2a and 3a were not directly compared in these studies.
An issue of further clinical significance that can be beneficially impacted with transporter technology is related to the controllable biodistribution of conjugates. By design, one can generate conjugates that stay where administered or others that distribute because uptake is made slower. Illustrative of this point, the biodistribution and pharmacokinetics of octaarginine−luciferin conjugates were evaluated in real time in living luciferase-expressing animals. 61 Luciferin and releasable luciferin−octaarginine conjugates were administered via IP injection into mice constitutively expressing firefly luciferase, and their respective real time biodistributions were compared ( Figure 8) . Because of the rapid cellular uptake of the octaarginine conjugate, it remained localized near the site of administration within the IP cavity (Figure 8, center panel) . Luciferin conjugates with control peptide, tetralysine, which does not display significant cellular uptake, stayed localized in the IP cavity but provided significantly poorer uptake into cells, as shown by the greatly reduced signal from released luciferin (Figure 8, left panel) . In dramatic contrast, free luciferin, when injected IP, distributed over the entire animal (Figure 8 , right panel). For solid tumors, the localization and uptake of the octaarginine conjugates could allow for greater tumor accumulation and correspondingly reduced systemic toxicity. Discussions of this study can be read in the works of Fonesca, Hampton, and others. 100−102 In a significant step toward a clinical approach to treating resistant ovarian cancer, we recently demonstrated that the Taxol−octaarginine conjugates showed effective cell kill in ex vivo ascites from drug-resistant ovarian cancer patients in multiple subtypes of ovarian carcinoma, including clear cell carcinoma and serous/papillary carcinoma ( Figure 9) . 62 All Taxol−octaarginine conjugates tested in ex vivo ascite cells displayed similar levels of cell kill, outperforming Taxol alone, which was inactive against these resistant cell samples from ovarian cancer patients. Of note, preliminary toxicity assays against normal human neutrophils with these conjugates indicate that the octaarginine conjugates were not significantly more toxic than Taxol alone. 62 As with all new agents, additional studies will address toxicity questions, including hematologic toxicity, with respect to both IV and IP administration, though recent successful studies of IV administration indicate that, at least for certain concentrations and formulations, 99 an appropriate therapeutic window would be accessible.
Though all conjugates in these studies utilized a cleavable disulfide linker, other bioactivatable mechanisms are readily amenable to incorporation for transporter−drug cleavage or targeting, such as protease-, esterase-, or phosphatase-cleavable moieties. 103−105 As demonstrated with the disulfide linkers, the rate of release of free drug can be controlled and tuned for specific applications. Another advantage of designing releasable transporter−drug conjugates is the ability to limit release to strictly intracellular release, which would serve to minimize side effects.
■ OUTLOOK
Multidrug resistance remains a major challenge in the treatment of a number of the world's most devastating diseases, including cancer, tuberculosis, and malaria. Strategies to address this resistance could have a profoundly beneficial impact on treating disease. In this review, we have focused on the use of molecular transporter−drug conjugates as a powerful and potentially general strategy to overcoming multidrug resistance mediated by Pgp-export pumps.
As discussed herein, transporter−drug conjugates often offer huge advantages over free drug alone and, in the case of known drugs that succumb to resistance, a remarkably fast path to clinical trials. Guanidinium-rich transporter−drug conjugates are water-soluble and thus offer many advantages in formulation and administration, as evident with Taxol, which can be formulated in small volumes of water and thus more rapidly administered, a benefit to both patients and clinicians. For many drugs, as exemplified by Taxol, the solubilizing effect allows one to avoid using toxic excipients (e.g., Cremophor EL). While Taxol complexed with proteins (e.g., Abraxane) 106 or with nanoparticles 53, 107 can be used for formulation and delivery, it is unclear whether they overcome Pgp-based resistance. Perhaps most importantly, in contrast to Taxol− protein complexes or nanoparticle complexes, drug−transporter conjugates are discrete, single molecule entities and thus provide greater batch-to-batch consistency and fewer regulatory problems. An often under-appreciated aspect of releasable drug conjugates is that they can be tuned to control drug payout from minutes to days, allowing for the significant clinical benefit of sustained release and avoiding peak−trough issues associated with free drug dosing and clearance. Finally and most importantly, drug−transporter conjugates dramatically change the properties of lipophilic drugs thereby evading Pgp-based resistance.
Though not yet experimentally explored, these transporter−drug conjugates should have application to other cancer types rendered difficult to treat due to export pumpmediated resistance, such as breast 18 and nonsmall-cell lung cancer. 19, 20 Though the work performed by our lab and others has been primarily focused on anthracyclines and taxanes, there are many other approved small molecule chemotherapeutics that suffer from efflux-mediated resistance, both in cancer and in other diseases. Because it has been shown that transporter−drug conjugates largely assume the physical properties of the transporter, this strategy should be broadly applicable to these other therapeutic classes in addressing efflux-related resistance.
While the current transporter−drug conjugates outperform the drug alone and are thus poised for clinical evaluation, it is expected for many cancers that transporter−drug conjugates could also be targeted to diseased tissue. The work described above showed passive targeting due to higher GSH levels in some cancer cells. Similarly, a recent study by Futaki and coworkers showed that octaarginine−drug conjugates show higher accumulation in tumor tissue. 98 To achieve, where necessary, even higher levels of intratumoral drug concentration and selectivity, more direct targeting efforts are possible. Foundational work by both the Tsien and Wender groups has shown that "kinetic targeting" with transporters provides a complementary strategy to thermodynamic targeting of monoclonal antibodies. Cationic guanidinium-rich transporters conjugated to an oligoanion sequence through a cleavable linking peptide do not enter cells due to charge neutralization that inactivates uptake. However, when the linker is cleaved by an overexpressed cell-surface protease expressed on tumor cells, the transporter−drug conjugate freely enters proximate cells. 103−105 The Tsien lab explored the use of a matrix metallo-protease-cleavable linker sequence, 104, 105 while our lab utilized a prostate-specific antigen sequence. 103 MMP-cleavable sequences have also been used with doxorubicin for cancer. 108 However, no one has explored this strategy in resistant cancers to date. Ligand conjugates such as folate or transferrin have also been explored by others, and nanoparticles have also been recognized for their potential as drug delivery agents to target and deliver chemotherapeutics to resistant cancers. 107 The opportunity to improve the formulation, administration, release, targeting, and efficacy of a chemotherapeutic drug by conjugation to a molecular transporter is significant, especially in connection with treating resistant disease. This transporterenabled strategy can greatly improve the prognosis of patients bearing resistant tumors. In the case of known drugs that succumb to resistance, this concept provides the basis for an exceptionally fast path to the clinic as conjugate synthesis is rapid and tunable, and the strategy does not require exploring a new mode of action but rather improving upon an existing drug. This strategy can be applied to a large number of existing chemotherapeutic agents, as well as drug leads, and its use extends to other important diseases where efflux-mediated resistance is manifest.
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